8/26/10 - Pursuit Vascular has been selected to present at LifeScience Alley's New Technology Showcase on December 8, 2010. The conference draws approximately 2000 life science professionals from 650+ organizations- Click Here
7/13/10 - Finance and Commerce Article feature Robert Ziebol, President/CEO of Pursuit Vascular - Click Here
7/1/10 - The Department of Employment and Economic Development announced that Pursuit Vascular is a qualified business for Minnesota Angel Tax Credit - Minnesota's Angel Tax Credit provides incentives to investors or investment funds that put money into startup and emerging companies focused on high technology or new proprietary technology Residents and Non-residents are eligible to participate for more information- Click Here
6/3/10 - Pursuit Vascular announces the international patent (PTC) protecting Cthe ClearGuard™ technology has published. For additional information contact info@pursuitvascular.com
5/26/10 - Pursuit Vascular announces that it received positive results from the International Searching Authority related to Pursuit Vascular’s ClearGuard™ international patent application. For additional information contact info@pursuitvascular.com
4/29/10 - The United States Patent and Trademark Office published two patent applications protecting the ClearGuard™ technology. For additional information contact info@pursuitvascular.com
3/25/10 - Robert Ziebol Featured Speaker at 6th Annual BioScience Conference in Worthington, MN-Click Here
1/4/10-News Release: Pursuit Vascular announces the successful completion of preliminary E Coli testing using the ClearGuard™ technology.
12/9/09-Twin Cities Business Magazine features Pursuit Vascular-Click for Details
11/3/09-Lommen Abdo October/November Newsletter- Click Here
11/3/09-News Release: Pursuit Vascular announces the filing of three patent applications covering the aspects of the ClearGuard™ technology and delivery system.
10/12/09-News Release: Pursuit Vascular announces the successful preliminary demonstration of the ClearGuard™ antimicrobial agent against the most common infectious micro organisms, including Methicillin-resistant Staphylococcus aureus (MRSA)
9/02/09 - Minnesota Cup Division Winners Announced, Twin Cities Biz Journal
8/21/09 - Minnesota Cup Finalists, Star Tribune
Learn more - Minnesota Cup
